Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma

Annals of Internal Medicine

Volumn 121, Issue 9, 1994, Pages 633-640

  Seymour, John F ^a   Gagel, Robert F ^b   Hagemeister, Frederick B ^b   Dimopoulos, Meletios A ^b   Cabanillas, Fernando ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERCALCEMIA; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0028596317     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-121-9-199411010-00001     Document Type: Article

References (45)

1. Burt ME, Brennan MF. Incidence of hypercaleemia and malignant neoplasm. Arch Surg. 1980;115:704-7.
2. Baechler R, Sauter C, Honegger HP, Oelz O. Hypercalciäie bei non-Hodgkin-lymphomen. Schweiz Med Wochenschr. 1985;115:332-4.
3. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Ensor JE, Guinee VF. Hypercalcemia of malignancy: incidence in a comprehensive cancer center [Abstract]. Proceedings of the American Society of Clinical Oncology. 1991; 10:131.
4. Rosenthal N, Insogna KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab. 1985;60:29-33.
5. Adams JS, Fernandez M, Gacad MA, Gill PS, Endres DB, Rasheed S, et al. Vitamin D metabolite-mediated hypercalcemia and hypercalciuria patients with AIDS- and non-AIDS-associated lymphoma. Blood. 1989;73:235-9.
6. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CY, Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med. 1984;100:1-6.
7. Devogelaer JP, Lambert M, Boland B, Godfraind C, Noel H, Nagant de Deuxchaisnes C. 1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports. Clin Rheumatol. 1990;9:404-10.
8. Mudde AH, van den Berg H, Boshuis PG, Breedveld FC, Markusse HM, Kluin PM, et al. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercaleemia. Cancer. 1987;59: 1543-6.
9. Scheinman SJ, Kelberman MW, Tatum AH, Zamkoff KW. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci. 1991;301:178-81.
10. Wada S, Kitamura H, Matsuura Y, Katayama Y, Ohkawa H, Kugai N, et al. Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma. Intern Med. 1992;31:968-72.
11. Reichet H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980-91.
12. Sensen HA, Schwarz P, McNair P, Hvldstrup L, Transb I, Calcium clamp technique: suppression of serum intact PTH by induced hypercalcaemia in normal man and primary hyperparathyroidism. Scand J Clin Lab Invest. 1992;52:457-65.
13. Hulter HN, Halloran BP, Toto RD, Peterson JC. Long-term control of plasma calcitriol concentration in dogs and humans. Dominant role of plasma calcium concentration in experimental hyperparathyroidism. J Clin Invest. 1985;76:695-702.
14. Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CY. The role of 1α25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 1977;59:756-60.
15. Broadus AE, Horst RL, Lang R, Littledike ET, Rasmussen H. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med. 1980;302:421-6.
16. Mason RS, Frankel T, Chan YL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984;100:59-61.
17. 3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983,72:1856-60.
18. Martin TJ, Moseley JM, Gillespie MT. Parathyroid hormone-related protein: biochemistry and molecular biology. Crit Rev Biochem Mol Biol. 1991;26:377-95.
19. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating in metastatic breast cancer. J Clin Endocrinol Metab. 1991;73:1309-15.
20. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet. 1992;339:164-7.
21. Pandian MR, Morgan CH, Carlton E, Segre GV. Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin Chem. 1992;38:282-8.
22. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science. 1987;238:1566-8.
23. Walker AT, Stewart AF, Korn EA, Shiratori T, Mitnick MA, Carpenter TO. Effect of parathyroid hormone-like peptides on 25-hydroxyvitamin D-1 α-hydroxylase activity in rodents. Am J Physiol. 1990;258: E297-303.
24. Ralston SH, Cowan RA, Robertson AG, Gardner MD, Boyle IT. Circulating vitamin D metabolites and hypercalcemia of malignancy. Acta Endocrinol (Copenh). 1984;106:556-63.
25. 3 production. Endocrinology. 1989;124:2057-62.
26. Lawson-Matlhew P, Clayton J, Guilland-Cumming D, Yates A, Preston E, Greaves M, et al. Vitamin D metabolism in myeloma. Br J Haematol. 1989;73:57-60.
27. Portale AA. Blood calcium, phosphorus and magnesium. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2d ed. New York: Raven Press; 1993:87.
28. Senba M, Kawai K. Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma [Letter]. Eur J Haematol. 1992;48:278-9.
29. Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, et al. Direct and indirect assessment of the parathyroid hormone reponse to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Bone Miner. 1991;12:113-21.
30. Blind E, Raue F, Meinel T, Wüter C, Ziegler R. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Horm Metab Res. 1993;25:40-4.
31. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab. 1993;76:801-5.
32. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993;341:1611-3.
33. Lemann J Jr. Urinary excretion of calcium, magnesium, and phosphorus. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2d ed. New York: Raven Press; 1993:50.
34. Wallon RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309-10.
35. Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab. 1984;58:91-8.
36. The Non-Hodgkin's Lymphoma Pathological Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-35.
37. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1993;82:1383-94.
38. Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dinydroxyvitamin D, production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab. 1987;65:1201-9.
39. Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Göring U, et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab. 1988;67:353-60.
40. Brown RC, Aston JP, Weeks I, Woodhead JS. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987;65:407-14.
41. Kao PC, van Heerden JA, Grant CS, Klee GC, Khosla S. Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc. 1992;67:637-45.
42. Blind E, Raue F, Meinel T, Wüter C, Ziegler R. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Horm Metab Res. 1993;25:40-4.
43. Jendiroba D, Seymour JF, Swan F, Cabanillas F. Hypercalcemia in intermediate grade non-Hodgkin's lymphoma (NHL) [Abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:379.
44. Warrell RP Jr. Metabolic emergencies. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: Lippincott; 1993: 2128.
45. Moses AM, Spencer H. Hypercalcemia in patients with malignant lymphuma. Ann Intern Med. 1963;59:531-ft.